TECH

BIO-TECHNE CORPORATION_February 4, 2026

0000842023false00008420232026-02-042026-02-04 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): February 4, 2026

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter) ​

Minnesota 0-17272 41-1427402

(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

​ ​ 55413 ​

614 McKinley Place NE Minneapolis, Minnesota 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

​ Securities registered pursuant to Section 12(b) of the Act: ​

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock

TECH

NASDAQ

​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. ​

☐ Emerging growth company

​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​

Item 2.02 Results of Operations and Financial Condition ​ A copy of the press release issued by Bio-Techne Corporation on February 4, 2026, describing the results of operations for the quarter and six months ended December 31, 2025, and its financial condition as of December 31, 2025 is attached hereto as Exhibit 99.1. ​ The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. ​ ​ Item 8.01 Other Events ​ A copy of the press release issued by Bio-Techne Corporation on February 4, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2. ​ Item 9.01 Financial Statements and Exhibits ​ (d) Exhibits

99.1 Press Release, dated February 4, 2026, announcing results of operations

99.2 Press Release, dated February 4, 2026, announcing cash dividend

​ ​

104 - Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​

​ ​ ​

SIGNATURE

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

BIO-TECHNE CORPORATION

​ ​

Date: February 4, 2026 By: /s/ Shane V. Bohnen

​ Shane V. Bohnen

​ Senior Vice President, General Counsel and Secretary

​ ​ ​ ​ ​

BIO-TECHNE CORPORATION_October 30, 2025

0000842023false00008420232025-10-302025-10-30 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): October 30, 2025

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter) ​

Minnesota 0-17272 41-1427402

(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

​ ​ 55413 ​

614 McKinley Place NE Minneapolis, Minnesota 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

​ Securities registered pursuant to Section 12(b) of the Act: ​

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock

TECH

NASDAQ

​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. ​

☐ Emerging growth company

​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​

Item 2.02 Results of Operations and Financial Condition ​ A copy of the press release issued by Bio-Techne Corporation (the “Company”) on November 5, 2025, describing the results of operations for the quarter ended September 30, 2025 and its financial condition as of September 30, 2025 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. ​ ​ Item 5.07 Submission of Matters to a Vote of Security Holders ​ A quorum was present at the Annual Meeting with 140,827,559 shares represented personally or by proxy, which represents approximately 90.45% of the outstanding shares of the Company's common stock. The voting results at the Annual Meeting were as set forth below. ​ Proposal No. 1 – The shareholders voted to set the number of directors at nine: ​

​

For Against Abstain Broker Non-Vote

140,278,598 314,005 234,956 0

​ Proposal No. 2 – The shareholders elected each of the nominees to the Board of Directors: ​

​ For Against Abstain Broker Non-Vote

Robert V. Baumgartner 134,015,677 6,570,465 241,417 0

Julie L. Bushman 136,076,243 4,511,497 239,819 0

John L. Higgins 135,131,210 5,460,347 236,002 0

Kim Kelderman 139,472,895 1,087,500 267,164 0

Joseph D. Keegan 136,272,153 4,315,695 239,711 0

Alpna Seth 134,628,283 5,957,489 241,787 0

Rupert Vessey 137,441,139 3,145,646 240,774 0

Judith Klimovsky 138,104,299 2,120,409 602,851 0

Amy Herr 139,257,947 1,323,873 245,739 0

Each nominee was elected by a majority voting standard defined in the Amended and Restated Articles of Incorporation. ​ Proposal No. 3 – The shareholders adopted a non-binding resolution approving the compensation of the Company’s named executive officers, as described in the Proxy Statement: 9,

For Against Abstain Broker Non-Vote

100,792,824 39,025,321 1,009,414 0

​ Proposal No. 4 – The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026. 40

​

For Against Abstain Broker Non-Vote

137,578,559 3,055,503 193,497 0

​ ​ ​ Item 8.01 Other Events ​ A copy of the press release issued by Bio-Techne Corporation on November 5, 2025, announcing a cash dividend is attached hereto as Exhibit 99.2. ​

Item 9.01 Financial Statements and Exhibits ​ (d) Exhibits

​ ​

99.1 Press Release, dated November 5, 2025, announcing results of operations

99.2 Press Release, dated November 5, 2025, announcing cash dividend

​ ​

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​ ​

SIGNATURE

​ Pursuant to the requirements of the Sec

0000842023false00008420232025-08-062025-08-06 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): August 6, 2025

BIO-TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter) ​

Minnesota 0-17272 41-1427402

(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

​ ​ 55413 ​

614 McKinley Place NE Minneapolis, Minnesota 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

​ Securities registered pursuant to Section 12(b) of the Act: ​

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock

TECH

NASDAQ

​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. ​

☐ Emerging growth company

​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​

Item 2.02 Results of Operations and Financial Condition ​ A copy of the press release issued by Bio-Techne Corporation on August 6, 2025, describing the results of operations for the quarter and year ended June 30, 2025, and its financial condition as of June 30, 2025 is attached hereto as Exhibit 99.1. ​ The information in this Form 8-K and the Exhibits attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. ​ ​ Item 8.01 Other Events ​ A copy of the press release issued by Bio-Techne Corporation on August 6, 2025 announcing a cash dividend is attached hereto as Exhibit 99.2. ​ Item 9.01 Financial Statements and Exhibits ​ (d) Exhibits

99.1 Press Release, dated August 6, 2025, announcing results of operations

99.2 Press Release, dated August 6, 2025, announcing cash dividend

​ ​

104 - Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​

​ ​ ​

SIGNATURE

​ Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

BIO-TECHNE CORPORATION

​ ​

Date: August 6, 2025 By: /s/ Shane V. Bohnen

​ Shane V. Bohnen

​ Senior Vice President, General Counsel and Secretary

​ ​ ​ ​ ​